Regulatory approval
Published by the Health Canada.
Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.
This is written in the approval document as:
MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HC (1) | BRAF p.V600E | Melanoma | Trametinib | |
| HC (1) | BRAF p.V600K | Melanoma | Trametinib | |
| HC (1) | BRAF p.V600E | High-Grade Glioma, NOS | Dabrafenib, Trametinib |